No efficacy or safety data released — stock reaction likely muted until Q3 2026 topline readouts. Monitor DECLARATION and LIBERTY data for VYD2311's differentiation vs. mRNA vaccines on tolerability. Historical calibration suggests neutral-to-negative drift at T+20 for this ticker; avoid directional positioning ahead of data.
Price Chart
Executive Summary
Invivyd dosed first participants in the LIBERTY Phase 3 trial evaluating VYD2311 (mAb) vs. mRNA COVID-19 vaccine, with topline data expected Q3 2026 alongside pivotal DECLARATION trial results. This is an early-stage clinical milestone with no efficacy or safety data yet — a routine pipeline update for a pre-revenue biotech.
Key Facts
- First participants dosed in LIBERTY Phase 3 trial (N≈210) comparing VYD2311 alone, mRNA vaccine alone, and co-administration.
- Topline data expected Q3 2026, concurrent with pivotal DECLARATION trial data.
- Primary endpoints are safety/tolerability through Day 6 (TEAEs, injection site reactions, systemic symptoms).
- LIBERTY is part of the broader REVOLUTION program aiming to position VYD2311 as a preferred COVID-19 prevention option over mRNA vaccines.
- VYD2311 shares antibody backbone with pemivibart (EUA for immunocompromised PrEP) and adintrevimab.
Financial Impact
No financial data disclosed; pre-revenue clinical-stage biotech.
Risk Factors
- Clinical trial failure or underwhelming safety/tolerability data vs. mRNA vaccines.
- Regulatory hurdles for BLA submission; reliance on EUA for pemivibart may not translate to VYD2311 approval.
- Viral evolution could reduce VYD2311 neutralizing activity against emerging variants.
- Enrollment delays or slower-than-expected recruitment could push Q3 2026 timeline.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3308710 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Sep 1, 2026 4w ago | 8-K | $0.8800 $0.8441 | ▼ −4.08% | ▼ −5.26% | $0.8221 (−6.58%) |
Aug 17, 2026 6w ago | 144 | $0.8680 $0.8198 | ▼ −5.55% | ▼ −4.56% | $0.8221 (−5.29%) |
Jul 6, 2026 12w ago | 8-K | $0.8340 $0.5350 | ▲ +35.85% | ▲ +35.29% | $0.8221 (+1.43%) |
Jun 16, 2026 15w ago | Press Release | $0.8918 $0.8008 | ▼ −10.20% | ▼ −10.40% | $0.8221 (−7.82%) |
Jun 11, 2026 16w ago | Institutional Cluster | $0.8125 $0.8037 | ▼ −1.08% | ▼ −2.97% | $0.8221 (+1.18%) |
Jun 9, 2026 16w ago | Press Release | $0.9900 $0.9418 | ▼ −4.87% | ▼ −6.32% | $0.8221 (−16.96%) |
Jun 1, 2026 17w ago | Press Release | $1.22 $0.8724 | ▼ −28.49% | ▼ −27.19% | $0.8221 (−32.61%) |
May 14, 2026 20w ago | 8-K | $1.16 $0.7700 | ▼ −33.62% | ▼ −32.76% | $0.8221 (−29.13%) |
May 14, 2026 20w ago | Press Release | $1.16 $0.7700 | ▼ −33.62% | ▼ −32.76% | $0.8221 (−29.13%) |
Apr 9, 2026 25w ago | 8-K | $1.78 $1.46 | ▼ −17.98% | ▼ −25.55% | $0.8221 (−53.81%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access